Brief: Wave Life Sciences Announces Positive Results From Phase 1B/2A Select-Hd Trial

Wave Life Sciences

25/06/2024 12:33

June 25 (Reuters) - WAVE Life Sciences Ltd  WVE.O :
    * WAVE LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM PHASE
1B/2A
SELECT-HD TRIAL WITH FIRST CLINICAL DEMONSTRATION OF
ALLELE-SELECTIVE MUTANT HUNTINGTIN LOWERING IN HUNTINGTON’S
DISEASE
    * WAVE LIFE SCIENCES LTD: STATISTICALLY SIGNIFICANT
INCREASES WERE
OBSERVED IN WTHTT PROTEIN VERSUS PLACEBO
    * WAVE LIFE SCIENCES LTD: GENERALLY SAFE AND WELL-TOLERATED
PROFILE ACHIEVED IN 30 MG MULTIDOSE COHORT
    * WAVE LIFE SCIENCES: SEES CURRENT CASH & CASH EQUIVALENTS
SUFFICIENT TO FUND OPERATIONS INTO Q4 2025

Source text for Eikon:  ID:nGNX5CWfPf 
Further company coverage:  WVE.O 

 ((Reuters.Briefs@thomsonreuters.com;))